- Home
- UROY vs TRVI Comparison
UROY vs TRVI Comparison
Compare UROY & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UROY
- TRVI
- Stock Information
- Founded
- UROY 2017
- TRVI 2011
- Country
- UROY Canada
- TRVI United States
- Employees
- UROY N/A
- TRVI N/A
- Industry
- UROY
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- UROY
- TRVI Health Care
- Exchange
- UROY Nasdaq
- TRVI Nasdaq
- Market Cap
- UROY 292.6M
- TRVI 341.4M
- IPO Year
- UROY N/A
- TRVI 2019
- Fundamental
- Price
- UROY $2.39
- TRVI $3.56
- Analyst Decision
- UROY Strong Buy
- TRVI Strong Buy
- Analyst Count
- UROY 2
- TRVI 8
- Target Price
- UROY $5.60
- TRVI $9.31
- AVG Volume (30 Days)
- UROY 2.0M
- TRVI 659.4K
- Earning Date
- UROY 03-14-2025
- TRVI 03-19-2025
- Dividend Yield
- UROY N/A
- TRVI N/A
- EPS Growth
- UROY 256.61
- TRVI N/A
- EPS
- UROY 0.03
- TRVI N/A
- Revenue
- UROY $27,478,292.00
- TRVI N/A
- Revenue This Year
- UROY N/A
- TRVI N/A
- Revenue Next Year
- UROY $34.24
- TRVI N/A
- P/E Ratio
- UROY $87.60
- TRVI N/A
- Revenue Growth
- UROY 31.26
- TRVI N/A
- 52 Week Low
- UROY $1.86
- TRVI $1.30
- 52 Week High
- UROY $3.76
- TRVI $4.68
- Technical
- Relative Strength Index (RSI)
- UROY 54.77
- TRVI 43.13
- Support Level
- UROY $2.20
- TRVI $3.63
- Resistance Level
- UROY $2.45
- TRVI $4.06
- Average True Range (ATR)
- UROY 0.12
- TRVI 0.30
- MACD
- UROY 0.02
- TRVI -0.11
- Stochastic Oscillator
- UROY 82.28
- TRVI 0.44
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.